IONS Stock Analysis: Buy, Sell, or Hold?
IONS - Ionis Pharmaceuticals, Inc. Common Stock
$75.99
0.10 (0.13%)
▲
5d:
+2.74%
30d:
+0.28%
90d:
+7.35%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Jul 29, 2026
Smart Money Accumulation
None View Scanner →
Strength: 8.0/10
Get Alerted When IONS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IONS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IONS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IONS is currently trading at $75.99, which is considered extended relative to its 30-day fair value range of $73.41 to $75.88.
Technical Outlook: Technically, IONS is in a strong uptrend. The price is approaching resistance at $77.31. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IONS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $104.91 (+38.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IONS is in a strong uptrend. The price is approaching resistance at $77.31. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IONS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $104.91 (+38.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$73.41 -
$75.88
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.2% below Wall St target ($104.91)
Trading Range Analysis
30-Day Trading Range
$73.41 -
$75.88
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$72.30
Resistance Level
$77.31
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-102.03
Wall Street Target
$104.91
(+38.2%)
Revenue Growth (YoY)
87.0%
Earnings Growth (YoY)
-43.7%
Profit Margin
-30.9%
Share & Embed Analysis
Last updated: June 23, 2026 3:59 PM ET
Data refreshes hourly during market hours. Next update: 4:59 PM
Data refreshes hourly during market hours. Next update: 4:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IONS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Kyle Jenne
SELL
4902 shares
2026-04-16
Brian Birchler
SELL
973 shares
2026-04-16
B Lynne Parshall
SELL
5000 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 60 BUY |
Advanced IONS Option Strategies
Professional options setups generated by AI based on today's IONS price and gamma walls.
